Your patients’ health is your top priority. Better understand your patient’s genes and how they may impact their medications. Genelex, a leader in the field of molecular diagnostics and genetics laboratory testing for more than 30 years, in conjunction with a leading clinical decision support tool (CDST), may help you bring more effective medication management especially for high risk polypharmacy patients. The CDST was inspired by a healthcare provider who wanted to establish a more automated and precise medication management system to enhance patient care.

Genelex is a leader in precision medication management. A pioneer in DNA testing since 1987, Genelex now focuses exclusively on pharmacogenetic testing. Backed by a powerful combination of innovative analytics software, state-of art laboratory facilities, and expert staff, Genelex has a longstanding commitment to the prevention of dangerous and life-threatening adverse drug events (ADEs).

23andMe has more than 12 million customers worldwide. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition. Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.